Lung Cancers Today
Advertisement
The Breakthrough Therapy Designation is based on results from the ES-SCLC cohort in the global phase 2 TROPiCS-03 study.
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.
This follows the FDA’s August 2024 move to grant Priority Review for the subcutaneous amivantamab BLA.
The phase 2 expansion portion of the trial will enroll approximately 50 patients at 10 to 15 sites in the United States.
Researchers say the conventional criteria may underestimate the condition in Asian patients with lung cancer.
A qualitative study of patients with NSCLC is providing insights into their experiences and perceptions.
Certain groups continue to experience higher rates of lung cancer mortality related to chronic lower respiratory diseases.
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Veterans with high socioeconomic deprivation experience suboptimal access to pre- and postoperative care for NSCLC.
The burden of disease is expected to increase to 4.62 million new cases and 3.55 million deaths by 2050.
Patients with NSCLC, treated with an immunotherapy regimen, have a higher risk of pneumonitis with decreased lung volume.
The approval is for certain patients with advanced, unresectable, or metastatic NSCLC with an NRG1 gene fusion.
Investigators evaluated the efficacy of durvalumab in the randomized, double-blind, placebo-controlled ADRIATIC trial.
An analysis of the CCTG BR.34 trial showed that bone metastasis correlated with worse outcomes in patients with NSCLC.
A novel dietary pattern was linked to lower lung cancer incidence in people who were former smokers
The study explored the relationship between sociodemographic disparities and access to minimally-invasive surgery for NSCLC.
Researchers evaluated the immunogenicity and safety of the COVID-19 vaccine in patients with lung cancer.
Detailed data from the trial will be presented at a medical meeting in 2025.
The recent report shows that the "breadth of tobacco-caused disparities continues to persist and expand."
The last Surgeon General’s report on tobacco-related disparities was released more than two decades ago in 1998.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.